Newsletter

068270 - Celltrion, Inc.

068270 Summary
Biopharma
Stock Price & Overview
₩188,100 +1,000 (+0.53%) Close · Sep 4, 2026 KST
KOSPI | ₩KRW | Close: ₩188,100  ≈ US$134  ·  Market cap ₩43.8tn (≈ $31.3bn)
Home › 068270 › Filings

Material matter: Korean phase 3 trial filed for CTP13 SC (Zymfentra) in rheumatoid arthritis

DART
Celltrion, Inc.
Filed Jul 24, 2026 KST · Filing · receipt 20260724800578

kstock has not written this one up. The title above is a translation of the Korean form name; the filing itself is on DART, in Korean.

Read the original on DART ↗ Korean. DART is Korea's electronic disclosure system, run by the Financial Supervisory Service — the filing equivalent of EDGAR.
Korean form name: 투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 한국 임상 3상 시험계획 신청(류마티스 관절염 환자))

068270

Price
₩188,100
Change
+0.53%
Market cap
₩43.8tn
Prev. close
₩187,100
068270 SummaryCompare to Peers

More 068270 filings

Celltrion Approves A ₩100bn Buyback And Says It Will Cancel All Of It

08/31/26

Fair Disclosure

08/31/26

5% Ownership Report — Large Holdings

08/28/26

Large business group status disclosure — quarterly, individual company

08/28/26

Company Statement on a Rumor or Media Report — “undetermined”

08/25/26

Material matter: Korean marketing approval sought for CTP51, a Keytruda biosimilar

08/24/26